Edit ID | Edit Comment | Time | |
---|---|---|---|
402470 | updating jak1 interp | 11/12/2018 3:41 PM |
Activating mutations in JAK1 SH2, pseudokinase and kinase domains have been reported in approximately 5-20% of cases of T-Cell Acute Lymphoblastic Leukemia and less than 5% of Acute Myeloid Leukemia. Some, but not all, of these mutations have been shown to be inhibitable by ATP-competitive JAK inhibitors or Type I interferon.
Activating mutations in JAK1 (SH2-, pseudokinase -and kinase- domains) have been reported in approximately 5-20% of cases of T-Cell Acute Lymphoblastic Leukemia, in "Ph-like ALL" and less than 5% of Acute Myeloid Leukemia. Some, but not all, of these mutations have been shown to be inhibitable by ATP-competitive JAK inhibitors or Type I interferon.